Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry Letters|August 16, 2005
A new class of high affinity thyromimetics containing a phenyl-naphthylene coreJon J Hangeland, Todd J Friends, Arthur M Doweyko, et al.Analytical Biochemistry|March 2, 2016
Characterization of monoacylglycerol acyltransferase 2 inhibitors by a novel probe in binding assaysZhengping Ma, Hannguang J Chao, Huji Turdi, et al.Bioorganic & Medicinal Chemistry Letters|December 28, 2007
Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide coreJon J Hangeland, Daniel L Cheney, Todd J Friends, et al.Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor betaJon J Hangeland, Arthur M Doweyko, Tamara Dejneka, et al.Bioorganic & Medicinal Chemistry Letters|January 17, 2015
Pyridine and pyridinone-based factor XIa inhibitorsJames R Corte, Tianan Fang, Jon J Hangeland, et al.ACS Medicinal Chemistry Letters|July 24, 2018
PK/PD Disconnect Observed with a Reversible Endothelial Lipase InhibitorJon J Hangeland, Lynn M Abell, Leonard P Adam, et al.Journal of Medicinal Chemistry|November 19, 2014
Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activityJon J Hangeland, Todd J Friends, Karen A Rossi, et al.Journal of Medicinal Chemistry|June 28, 2019
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic EfficacyMichael M Miller, Jacques Banville, Todd J Friends, et al.Journal of Medicinal Chemistry|October 6, 2021
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic DisordersHuji Turdi, Hannguang Chao, Jon J Hangeland, et al.Pageof 1